MorphoSys (NASDAQ:MOR) Receives Buy Rating from JMP Securiti

JMP Securities reiterated their buy rating on shares of MorphoSys (NASDAQ:MOR – Get Rating) in a report issued on Friday morning, MarketBeat Ratings reports. The brokerage currently has a $41.00 price target on the stock. MOR has been the subject of several other research reports. Zacks Investment Research raised MorphoSys from a sell rating to […]

Related Keywords

, Morgan Stanley , Goldman Sachs Group Inc , Morphosys Company Profile Get Rating , Zacks Investment Research , Quadrant Capital Group , Us Bancorp , Get Rating , Marketbeat Ratings , Investment Research , Capital Group , Goldman Sachs Group , Sachs Group , Sys Company Profile , Proprietary Development , Partnered Discovery , Morphosys , Nasdaq Mor , Humor , Medical , Reiterated Rating , Jmp Securities ,